Currently, trastuzumab in combination with chemotherapy is considered the standard treatment for patients with HER-2-positive advanced gastric cancer, and immunohistochemistry is the primary HER-2 testing method: a score of 3+ confirms eligibility for trastuzumab therapy, whereas a 1+ score indicates no overexpression. The gene discussed is ERBB2; the disease is gastric cancer.